TD Cowen Reiterates Buy Rating on Krystal Biotech
TD Cowen reaffirms its buy rating on Krystal Biotech with a $403 price target.
Key Points
- TD Cowen reiterated its buy rating on Krystal Biotech, Inc. (KRYS) with a price target of $403 on June 18, 2026.
- Krystal Biotech shares are trading at $341.66, with a market cap of about $10.07 billion and a P/E ratio of 45.68.
- FMR LLC increased its holdings in Krystal Biotech by 24,359 shares, totaling 4,373,987 shares valued at approximately $1.13 billion.
On June 18, 2026, TD Cowen reaffirmed its buy rating on Krystal Biotech, Inc. (NASDAQ: KRYS) with a price target of $403. The stock is currently trading at $341.66.
Analysts Set New Price Targets
Ritu Baral from TD Cowen maintained a buy rating on Krystal Biotech with a price target of $403. This reflects continued confidence in the company’s growth potential. On June 16, HC Wainwright & Co. also maintained a buy rating, setting a target of $361. Citigroup and Evercore ISI Group have kept their buy ratings with targets of $378 and $300, respectively.
Other Institutional Activity in Krystal Biotech
FMR LLC increased its stake in Krystal Biotech by 24,359 shares, bringing its total to 4,373,987 shares valued at approximately $1.13 billion. BlackRock, Inc. also added 2,639 shares to hold a total of 3,940,456 shares worth around $1.02 billion. Meanwhile, State Street Corp reduced its position by 27,869 shares, resulting in a total of 1,314,434 shares valued at about $339.5 million.
Krystal Biotech Stock Snapshot
Shares of Krystal Biotech are trading near $341.66. The company has a market capitalization of approximately $10.07 billion and a price-to-earnings ratio of 45.68. It has a 52-week low of $130.17 and a high of $347.67, with a 50-day moving average of $292.35 and a 200-day moving average of $243.19. The stock’s beta is 0.528, indicating lower volatility compared to the market.
Recent Earnings
Krystal Biotech reported revenue of $417.3 million, showing a growth rate of 31.9%. The company has a net margin of 53.93% and a return on equity of 19.90%. Its next earnings release is scheduled for August 3, 2026.
Insider Buying and Selling at Krystal Biotech, Inc.
In planned transactions, President and CEO Krish Krishnan sold 25,000 shares on June 4, 2026, at an average price of $308.12. Similarly, President of R&D Suma Krishnan sold 25,000 shares on the same date at an average price of $308.12. EVP and General Counsel John Charles Thomas sold 642 shares on May 26, 2026, at an average price of $302.03.
About Krystal Biotech
Krystal Biotech, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on developing genetic medicines to address diseases with high unmet needs. Founded in 2016, the company is led by CEO Krish Krishnan and employs 295 people. Krystal Biotech has commercialized VYJUVEK for treating dystrophic epidermolysis bullosa and is developing several other treatments in various stages of clinical trials.
Bottom Line
TD Cowen's reaffirmation of its buy rating with a $403 target reflects continued confidence in Krystal Biotech's prospects. The stock remains a point of interest for institutional investors, with notable activity from major funds like FMR LLC and BlackRock. As always, investors should note that analyst ratings are based on past performance and are not indicative of future results.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.